Filing scope and business context
Important entity clarification: This filing is CF Finance Acquisition Corp. III (CFAC), a blank-check SPAC—not an operating-company 10-K for AEye, Inc. The reporting period is the fiscal year ended December 31, 2020; it does not provide standalone fourth-quarter results. AEye is discussed as the proposed merger target in a transaction agreement signed February 17, 2021, after year-end.
CFAC completed its IPO on November 17, 2020, raising $230 million gross from 23 million units, and sold $5 million of private-placement units. It deposited $230 million in the trust account. In February 2021, CFAC agreed to merge with AEye at an indicated equity value of $1.9 billion, subject to closing conditions, and secured a $225 million PIPE at $10 per share.
Financial results and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | None; CFAC had not begun operating | None |
| General and administrative costs | $115,204 | $98 |
| Related-party administrative expense | $14,333 | None |
| Franchise tax expense | $24,165 | $450 |
| Interest income on trust investments | $819 | None |
| Net loss | $152,883 | $548 |
Margins are not meaningful because the company generated no revenue. The filing reports no operating cash flow in either year. In 2020, investing activities used $230 million, principally for the trust deposit; financing activities provided $229,976,250. Cash ended the year at $1,250.
At December 31, 2020, total assets were $230,804,152, including $230,000,819 in trust-account cash equivalents. Current liabilities were $484,647, including $427,612 borrowed under the sponsor loan; stockholders’ equity was $5,000,005. Working capital was negative approximately $45,900. The filing presents $225,319,500 of Class A shares subject to possible redemption as temporary equity, outside stockholders’ equity.
Changes, outlook, and risks
- Compared with 2019, the net loss increased from $548 to $152,883, largely reflecting IPO-year public-company, administrative, and franchise-tax expenses. The business remained pre-operational.
- Management expected sponsor loan capacity to provide sufficient working capital through the earlier of a business combination or one year from the filing. The sponsor had committed up to $1.75 million for working capital; approximately $428,000 was outstanding at year-end.
- The SPAC’s initial combination deadline was May 17, 2021, extendable up to four times by four months, to September 17, 2022. Each extension required a $2.3 million sponsor loan deposit. Sponsor funding of extensions was not guaranteed.
- The AEye transaction remained subject to stockholder approvals and customary conditions, including regulatory approvals. The proposed PIPE was a financing commitment, not year-end cash.
- Notable related-party economics include a monthly $10,000 payment to the sponsor for office and administrative services, a contingent marketing fee to Cantor of 3.5% of base IPO proceeds plus 5.5% of over-allotment proceeds upon a completed combination, and a customary financial-advisory fee to affiliate CF&Co. The filing does not state a clear amount for the advisory fee.
- Key risks include failure to complete a transaction before the deadline, redemptions reducing cash available, need for additional financing, conflicts arising from sponsor and management affiliations and other SPAC roles, claims against trust assets, and warrants becoming worthless if no combination closes. COVID-19 could affect the company or its target search, but the specific impact was not determinable.
Investor verification points
- Confirm that this CFAC filing is not AEye’s operating-company financial report; review AEye’s own financial statements and the transaction registration materials for its operating results, cash needs, and risks.
- Verify the AEye merger’s final terms, closing status, approvals, PIPE funding, redemption levels, and resulting cash available to the combined company.
- Reconcile the SPAC’s trust balance, redeemable-share classification, sponsor loan balance, and working-capital deficit against the audited statements and subsequent filings.
- Review the final transaction disclosures for affiliate fees, dilution from founder shares and warrants, lock-ups, and any additional financing or debt.
- Assess trust-account creditor protections and the sponsor’s ability to meet any indemnification obligations; the filing says that ability is not assured.